Fenwick is currently ranked #1 issuer-side for public offerings in 2021 by deal value, according to Deal Point Data. The firm has maintained market dominance in direct listings launched this year, remaining #1 issuer-side in direct listings in 2021 by deal count, according to Deal Point Data.

Fenwick is a market leader and one of the top law firms in the United States for representing leading technology and life sciences companies in their initial public offerings and other equity and debt offerings. We advise clients on traditional IPOs, as well as other innovative public offering structures, including special purpose acquisition company offerings (SPACs), direct listings and reverse mergers. Our team represents investor-backed startups and high-growth companies, as well as high-profile public companies, and works closely with many of the most active investment banking firms.

Fenwick’s team was named a Capital Markets Group of the Year by Law360 in 2021 and recognized by Forbes as one of America’s Top Trusted Corporate Law Firms in 2019. In 2021, Chambers USA also honored Fenwick among California’s leading firms for capital markets.

  • Underwriter Representation
    • Citigroup
    • Credit Suisse
    • Day One Biopharmaceuticals
    • Deutsche Bank
    • DICE Therapeutics
    • Goldman Sachs
    • J.P. Morgan
    • Morgan Stanley
    • Piper Sandler
    • UBS

Practice Services

  • Counsel technology and life sciences clients in initial public offerings and other equity and debt offerings
  • Represent some of the most active investment banking firms for technology and life sciences transactions
  • Advise publicly traded companies in ongoing corporate governance, disclosure and securities law matters
  • Provide M&A, executive compensation, tax, intellectual property, litigation and internal investigations guidance


Don’t have an account yet?